China Medical System Holdings Ltd 2025 AR2
The report outlines China Medical System Holdings Limited's strategic transformation and financial performance for the fiscal year 2025. The company achieved a 9.9% increase in turnover to RMB8,212.1 million, driven by the growth of innovative and exclusive products. Key milestones included the approval of two new drugs, Lumirix and Desidustat, and the progression of several clinical-stage pipelines. Additionally, the company advanced its international expansion with a secondary listing on the Singapore Exchange and proposed the spin-off and separate listing of its skin health subsidiary, Dermavon, on the Hong Kong Stock Exchange.
Company: China Medical System Holdings Ltd
Sector: Health Care
Country: Hong Kong
Year: 2025
Type: AR2
Pages: 180
China Medical System Holdings Ltd
Annual Report
The report outlines China Medical System Holdings Limited's strategic transformation and financial performance for the fiscal year 2025. The company achieved a 9.9% increase in turnover to RMB8,212.1 million, driven by the growth of innovative and exclusive products. Key milestones included the approval of two new drugs, Lumirix and Desidustat, and the progression of several clinical-stage pipelines. Additionally, the company advanced its international expansion with a secondary listing on the Singapore Exchange and proposed the spin-off and separate listing of its skin health subsidiary, Dermavon, on the Hong Kong Stock Exchange.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jan 1, 2025 - Dec 31, 2025
Fiscal Year
2025
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees